North America Professional Acne Medication Market by Acne Type (Inflammatory Acne and Non-inflammatory Acne), by Formulation (Topical Medications and Oral Medications), by Therapeutic Class (Retinoids, Antibiotics, Salicylic Acid, Benzoyl Peroxide, and Others), and by Distribution Channel (Med Spa, Aesthetician, Dermatologist, and Other Professional Channels) – Opportunity Analysis and Industry Forecast, 2024–2030

North America Professional Acne Medication Market

Industry:  Consumer Goods | Publish Date: Feb 2024 | No of Pages:  132 | No. Tables:  90 | No. Figures:  55

Market Definition

North America Professional Acne Medication Market was valued at USD 1509.69 million in 2023 and is predicted to reach USD 2122.38 million by 2030, with a CAGR of 5.0% from 2024 to 2030. The professional acne medication market refers to specialized skincare formulations prescribed by dermatologists for targeted and effective acne treatment, addressing both inflammatory and non-inflammatory lesions while preventing scarring. These formulations offer advantages such as potent and tailored ingredients, often surpassing over-the-counter options.

Widely utilized in dermatology practices, professional acne medications cater to individuals with severe or persistent acne concerns, ensuring a higher level of efficacy and control. As the demand for advanced skincare rises, this market remains pivotal, providing personalized and medically guided approaches for achieving clearer and healthier skin. 

Growing Number of Dermatology Clinics Boosts the Growth of Market

The expansion of skincare clinics, dermatology practices, and medical spas across North America has played a pivotal role in driving the growth of the professional acne medication market. According to the estimate of the U.S. Bureau of Labor Statistics in 2022, there were a total number of 11,640 dermatologists working in the United States, doing both medical and dermatological treatments.

The presence of these healthcare facilities in various urban and suburban areas ensures that people have easier access to specialized dermatological care. As a result, patients can receive personalized treatment plans that cater to their specific needs, whether they are dealing with mild or severe acne. The convenience and availability of such clinics and practices have made it more convenient for individuals to address their acne concerns, contributing to the overall expansion of the professional acne medication market in the region.

 

Technological Advancements Fuel the Market

Advances in dermatological treatments, such as laser therapy, chemical peels, and microdermabrasion, have provided effective and less invasive options for acne treatment, attracting patients looking for quicker results with minimal downtime. For instance, in March 2023, Cetaphil, a skincare brand in the US, introduced a new AI-powered skin analysis tool. This tool provides customers with personalized advice and product recommendations based on their unique skin requirements, such as acne, redness, hydration, dark spots, and wrinkles. As a result, it boosts the growth of the professional acne medication market by generating greater interest in and demand for customized and professional-grade acne treatments.

 

The High Treatment Costs of Professional Acne Medication Hinder Market Growth 

High treatment costs in the professional acne medication market encompass expenses associated with dermatologist visits and advanced procedures, deterring potential patients and limiting market growth. Dermatologist consultations often involve fees and additional diagnostic costs, which may not be covered by health insurance, posing a financial burden. 

Customized Acne Treatments Create Opportunity for Market Growth

The adoption of customized treatment solutions in the professional acne medication market represents a remarkable opportunity. The region's diverse population, with varying genetic backgrounds and skin types, underscores the importance of tailoring treatments to individual needs. By incorporating genetic and skin type considerations into treatment plans, dermatologists can enhance the precision and effectiveness of their interventions.

As a result, it is likely to attract a growing number of individuals to seek professional acne treatment, thereby fostering the market's expansion and ensuring that patients receive highly customized care to address their specific needs. This patient-centric and targeted approach aligns with the increasing demand for personalized healthcare, positioning the North American professional acne medication market for a promising future.

The U.S. Holds the Dominant Market Share in the North American Market

Continuous advancements in dermatological technology have significantly driven the growth of the professional acne medication market in the U.S. These advances include the integration of innovative treatments like photo pneumatic technology, exemplified by the Thera Clear X Acne System, which is engineered for the treatment of mild-to-moderate acne vulgaris.

Additionally, Legit. Health launched an artificial intelligence algorithm, ALADIN (Automatic Lesion and Density Index), which played a pivotal role in the future of acne treatment. ALADIN, developed by, leverages computer vision technology to rapidly and accurately analyse acne lesions, offering personalized treatment recommendations within seconds.

Additionally, in the U.S. market, the adoption of customized treatment plans has proven to be a pivotal driver of growth in the professional acne medication sector. Dermatologists are increasingly tailoring treatment regimens to suit the specific needs of individual patients, taking into account genetic predispositions and distinct skin types. The appeal of treatments precisely aligned with individual requirements propelled the demand for professional acne medication, fostering the market's expansion in this region.

Mexico is Expected to Show Steady Growth in the Market

Telehealth advancements have become a driving force in the professional acne medication industry in Mexico, particularly in the wake of the COVID-19 pandemic. Telemedicine is rapidly bridging healthcare accessibility gaps in the country, despite facing challenges like limited technology access, legal hurdles, infrastructure constraints, cultural and language barriers, and payment issues.

The technology with the potential to greatly benefit underserved communities with limited access to healthcare services, is promising continued growth and improved patient care in the professional acne medication industry in Mexico. Moreover, the professional acne medication market in Mexico is propelled by increasing beauty and aesthetic concerns.

With a growing emphasis on personal appearance and bolstering self-esteem, individuals in Mexico are increasingly turning to professional acne treatments to attain clear and healthy skin. As a result, the market continues to expand as more people recognize the importance of professional treatments in achieving their beauty and wellness goals, positioning Mexico as a burgeoning hub for professional acne medication services.

 

Competitive Landscape

The North American professional acne medication industry includes several market players such as Almirall SA, Bausch Health Companies, Inc., GlaxoSmithKline Plc (GSK), Galderma SA, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Johnson & Johnson, STRATA Skin Sciences, Inc., Mayne Pharma Group Limited, and Pfizer, Inc., and others.

North America Professional Acne Medication Market Key Segments

By Acne Type    

  • Inflammatory Acne 

  • Non-inflammatory Acne 

By Formulation    

  • Topical Medications

  • Oral Medications 

By Therapeutic Class

  • Retinoids

  • Antibiotics

  • Salicylic Acid

  • Benzoyl Peroxide

  • Others

By Distribution Channel

  • Med Spa

  • Aesthetician

  • Dermatologist

  • Other Professional Channels

By Geography

  • North America

    • U.S.

    • Canada

    • Mexico        

REPORT SCOPE AND SEGMENTATION:

Parameters

Details

Market Size in 2023

USD 1509.69 Million

Revenue Forecast in 2030

USD 2122.38 Million

Growth Rate

CAGR of 5.0% from 2024 to 2030

Analysis Period

2023–2030

Base Year Considered

2023

Forecast Period

2024–2030

Market Size Estimation

Million (USD)

Growth Factors

Rapid growth of dermatology clinics.

Influence of technological advancement.

Countries Covered

3

Companies Profiled

10

Market Share

Available for 10 companies

Customization Scope

Free customization (equivalent up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope.

Pricing and Purchase Options

Avail customized purchase options to meet your exact research needs.

Test

1      INTRODUCTION

           1.1      REPORT DESCRIPTION

           1.2      RESEARCH METHODOLOGY

                         1.2.1      SECONDARY RESEARCH

                         1.2.2      DATA ANALYSIS FRAMEWORK

                         1.2.3      MARKET SIZE ESTIMATION

                         1.2.4      FORECASTING

                         1.2.5      PRIMARY RESEARCH AND DATA VALIDATION

2      NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET – EXECUTIVE SUMMARY

           2.1.      MARKET SNAPSHOT, 2023 - 2030, MILLION USD

3      PORTER’S FIVE FORCE MODEL ANALYSIS

           3.1      BARGAINING POWER OF SUPPLIERS

           3.2      BARGAINING POWER OF BUYERS

           3.3      DEGREE OF COMPETITION

           3.4      THREAT OF SUBSTITUTE

           3.5      THREAT OF NEW ENTRANTS

4      MARKET SHARE ANALYSIS

           4.1      MARKET SHARE ANALYSIS OF TOP PROVIDERS, 2023

5      MARKET DYNAMICS

           5.1      GROWTH DRIVERS

                         5.1.1      DRIVER 1

                         5.1.2      DRIVER 2

                         5.1.3      DRIVER 3

                         5.1.4      DRIVER 4

           5.2      CHALLENGES

                         5.2.1      CHALLENGE 1

                         5.2.2      CHALLENGE 2

                         5.2.3      CHALLENGE 3

                         5.2.4      CHALLENGE 4

           5.3      OPPORTUNITIES

                         5.3.1      OPPORTUNITY 1

                         5.3.2      OPPORTUNITY 2

6      NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET BY ACNE TYPE

           6.1      OVERVIEW

           6.2      INFLAMMATORY ACNE

                         6.2.1      INFLAMMATORY ACNE  MARKET, BY COUNTRY

           6.3      NON-INFLAMMATORY ACNE

                         6.3.1      NON-INFLAMMATORY ACNE MARKET, BY COUNTRY

7      NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET BY FORMULATION

           7.1      OVERVIEW

           7.2      TOPICAL MEDICATIONS

                         7.2.1      TOPICAL MEDICATIONS MARKET, BY COUNTRY

           7.3      ORAL MEDICATIONS

                         7.3.1      ORAL MEDICATIONS  MARKET, BY COUNTRY

8      NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET BY THERAPEUTIC CLASS

           8.1      OVERVIEW

           8.2      RETINOIDS

                         8.2.1      RETINOIDS MARKET, BY COUNTRY

           8.3      ANTIBIOTICS

                         8.3.1      ANTIBIOTICS MARKET, BY COUNTRY

           8.4      SALICYLIC ACID

                         8.4.1      SALICYLIC ACID MARKET, BY COUNTRY

           8.5      BENZOYL PEROXIDE

                         8.5.1      BENZOYL PEROXIDE MARKET, BY COUNTRY

           8.6      OTHERS

                         8.6.1      OTHERS MARKET, BY COUNTRY

9      NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET BY DISTRIBUTION CHANNEL

           9.1      OVERVIEW

           9.2      MED SPA

                         9.2.1      MED SPA MARKET, BY COUNTRY

           9.3      AESTHETICIAN

                         9.3.1      AESTHETICIAN MARKET, BY COUNTRY

           9.4      DERMATOLOGIST

                         9.4.1      DERMATOLOGIST MARKET, BY COUNTRY

           9.5      OTHER PROFESSIONAL CHANNELS

                         9.5.1      OTHER PROFESSIONAL CHANNELS MARKET, BY COUNTRY

10   NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET, BY COUNTRY

           10.1   OVERVIEW

           10.2   UNITED STATES

                         10.2.1   NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET, BY ACNE TYPE

                         10.2.2   NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET, BY FORMULATION

                         10.2.3   NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS

                         10.2.4   NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL

           10.3   CANADA

                         10.3.1   NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET, BY ACNE TYPE

                         10.3.2   NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET, BY FORMULATION

                         10.3.3   NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS

                         10.3.4   NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL

           10.4   MEXICO

                         10.4.1   NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET, BY ACNE TYPE

                         10.4.2   NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET, BY FORMULATION

                         10.4.3   NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS

                         10.4.4   NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL

11   COMPANY PROFILES

           11.1   ALMIRALL SA

                         11.1.1   COMPANY OVERVIEW

                         11.1.2   COMPANY SNAPSHOT

                         11.1.3   OPERATING BUSINESS SEGMENTS

                         11.1.4   PRODUCT PORTFOLIO

                         11.1.5   BUSINESS PERFORMANCE

                         11.1.6   BUSINESS SEGMENTS

                         11.1.7   GEOGRAPHIC SEGMENTS

                         11.1.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         11.1.9   PRIMARY MARKET COMPETITORS

           11.2   BAUSCH HEALTH COMPANIES, INC.

                         11.2.1   COMPANY OVERVIEW

                         11.2.2   COMPANY SNAPSHOT

                         11.2.3   OPERATING BUSINESS SEGMENTS

                         11.2.4   PRODUCT PORTFOLIO

                         11.2.5   BUSINESS PERFORMANCE

                         11.2.6   BUSINESS SEGMENTS

                         11.2.7   GEOGRAPHIC SEGMENTS

                         11.2.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         11.2.9   PRIMARY MARKET COMPETITORS

           11.3   GLAXOSMITHKLINE PLC (GSK)

                         11.3.1   COMPANY OVERVIEW

                         11.3.2   COMPANY SNAPSHOT

                         11.3.3   OPERATING BUSINESS SEGMENTS

                         11.3.4   PRODUCT PORTFOLIO

                         11.3.5   BUSINESS PERFORMANCE

                         11.3.6   BUSINESS SEGMENTS

                         11.3.7   GEOGRAPHIC SEGMENTS

                         11.3.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         11.3.9   PRIMARY MARKET COMPETITORS

           11.4   GALDERMA SA

                         11.4.1   COMPANY OVERVIEW

                         11.4.2   COMPANY SNAPSHOT

                         11.4.3   OPERATING BUSINESS SEGMENTS

                         11.4.4   PRODUCT PORTFOLIO

                         11.4.5   BUSINESS PERFORMANCE

                         11.4.6   BUSINESS SEGMENTS

                         11.4.7   GEOGRAPHIC SEGMENTS

                         11.4.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         11.4.9   PRIMARY MARKET COMPETITORS

           11.5   SUN PHARMACEUTICAL INDUSTRIES LIMITED

                         11.5.1   COMPANY OVERVIEW

                         11.5.2   COMPANY SNAPSHOT

                         11.5.3   OPERATING BUSINESS SEGMENTS

                         11.5.4   PRODUCT PORTFOLIO

                         11.5.5   BUSINESS PERFORMANCE

                         11.5.6   BUSINESS SEGMENTS

                         11.5.7   GEOGRAPHIC SEGMENTS

                         11.5.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         11.5.9   PRIMARY MARKET COMPETITORS

           11.6   TEVA PHARMACEUTICAL INDUSTRIES LTD.

                         11.6.1   COMPANY OVERVIEW

                         11.6.2   COMPANY SNAPSHOT

                         11.6.3   OPERATING BUSINESS SEGMENTS

                         11.6.4   PRODUCT PORTFOLIO

                         11.6.5   BUSINESS PERFORMANCE

                         11.6.6   BUSINESS SEGMENTS

                         11.6.7   GEOGRAPHIC SEGMENTS

                         11.6.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         11.6.9   PRIMARY MARKET COMPETITORS

           11.7   JOHNSON AND JOHNSON

                         11.7.1   COMPANY OVERVIEW

                         11.7.2   COMPANY SNAPSHOT

                         11.7.3   OPERATING BUSINESS SEGMENTS

                         11.7.4   PRODUCT PORTFOLIO

                         11.7.5   BUSINESS PERFORMANCE

                         11.7.6   BUSINESS SEGMENTS

                         11.7.7   GEOGRAPHIC SEGMENTS

                         11.7.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         11.7.9   PRIMARY MARKET COMPETITORS

           11.8   STRATA SKIN SCIENCES, INC.

                         11.8.1   COMPANY OVERVIEW

                         11.8.2   COMPANY SNAPSHOT

                         11.8.3   OPERATING BUSINESS SEGMENTS

                         11.8.4   PRODUCT PORTFOLIO

                         11.8.5   BUSINESS PERFORMANCE

                         11.8.6   BUSINESS SEGMENTS

                         11.8.7   GEOGRAPHIC SEGMENTS

                         11.8.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         11.8.9   PRIMARY MARKET COMPETITORS

           11.9   MAYNE PHARMA GROUP LIMITED

                         11.9.1   COMPANY OVERVIEW

                         11.9.2   COMPANY SNAPSHOT

                         11.9.3   OPERATING BUSINESS SEGMENTS

                         11.9.4   PRODUCT PORTFOLIO

                         11.9.5   BUSINESS PERFORMANCE

                         11.9.6   BUSINESS SEGMENTS

                         11.9.7   GEOGRAPHIC SEGMENTS

                         11.9.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         11.9.9   PRIMARY MARKET COMPETITORS

           11.10   PFIZER, INC.

                         11.10.1   COMPANY OVERVIEW

                         11.10.2   COMPANY SNAPSHOT

                         11.10.3   OPERATING BUSINESS SEGMENTS

                         11.10.4   PRODUCT PORTFOLIO

                         11.10.5   BUSINESS PERFORMANCE

                         11.10.6   BUSINESS SEGMENTS

                         11.10.7   GEOGRAPHIC SEGMENTS

                         11.10.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         11.10.9   PRIMARY MARKET COMPETITORS

LIST OF TABLES

TABLE 1. NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE, 2023-2030, (MILLION USD)

TABLE 2. INFLAMMATORY ACNE, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 3. NON-INFLAMMATORY ACNE, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 4. NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION, 2023-2030, (MILLION USD)

TABLE 5. TOPICAL MEDICATIONS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 6. ORAL MEDICATIONS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 7. NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS, 2023-2030, (MILLION USD)

TABLE 8. RETINOIDS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 9. ANTIBIOTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 10. SALICYLIC ACID, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 11. BENZOYL PEROXIDE, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 12. OTHERS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 13. NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL, 2023-2030, (MILLION USD)

TABLE 14. MED SPA, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 15. AESTHETICIAN, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 16. DERMATOLOGIST, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 17. OTHER PROFESSIONAL CHANNELS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 18. NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 19. UNITED STATES NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE, 2023-2030, (MILLION USD)

TABLE 20. UNITED STATES NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION, 2023-2030, (MILLION USD)

TABLE 21. UNITED STATES NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS, 2023-2030, (MILLION USD)

TABLE 22. UNITED STATES NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL, 2023-2030, (MILLION USD)

TABLE 23. CANADA NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE, 2023-2030, (MILLION USD)

TABLE 24. CANADA NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION, 2023-2030, (MILLION USD)

TABLE 25. CANADA NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS, 2023-2030, (MILLION USD)

TABLE 26. CANADA NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL, 2023-2030, (MILLION USD)

TABLE 27. MEXICO NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE, 2023-2030, (MILLION USD)

TABLE 28. MEXICO NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION, 2023-2030, (MILLION USD)

TABLE 29. MEXICO NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS, 2023-2030, (MILLION USD)

TABLE 30. MEXICO NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL, 2023-2030, (MILLION USD)

TABLE 31. ALMIRALL S.A.: COMPANY SNAPSHOT

TABLE 32. ALMIRALL S.A.: OPERATING BUSINESS SEGMENTS

TABLE 33. ALMIRALL S.A.: PRODUCT PORTFOLIO

TABLE 34. ALMIRALL S.A.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 35. ALMIRALL S.A.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 36. ALMIRALL S.A.: KEY STRATERGY

TABLE 37. BAUSCH HEALTH COMPANIES, INC.: COMPANY SNAPSHOT

TABLE 38. BAUSCH HEALTH COMPANIES, INC.: OPERATING BUSINESS SEGMENTS

TABLE 39. BAUSCH HEALTH COMPANIES, INC.: PRODUCT PORTFOLIO

TABLE 40. BAUSCH HEALTH COMPANIES, INC.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 41. BAUSCH HEALTH COMPANIES, INC.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 42. BAUSCH HEALTH COMPANIES, INC.: KEY STRATERGY

TABLE 43. GLAXOSMITHKLINE PLC (GSK): COMPANY SNAPSHOT

TABLE 44. GLAXOSMITHKLINE PLC (GSK): OPERATING BUSINESS SEGMENTS

TABLE 45. GLAXOSMITHKLINE PLC (GSK): PRODUCT PORTFOLIO

TABLE 46. GLAXOSMITHKLINE PLC (GSK): SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 47. GLAXOSMITHKLINE PLC (GSK): SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 48. GLAXOSMITHKLINE PLC (GSK): KEY STRATERGY

TABLE 49. GALDERMA S.A.: COMPANY SNAPSHOT

TABLE 50. GALDERMA S.A.: OPERATING BUSINESS SEGMENTS

TABLE 51. GALDERMA S.A.: PRODUCT PORTFOLIO

TABLE 52. GALDERMA S.A.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 53. GALDERMA S.A.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 54. GALDERMA S.A.: KEY STRATERGY

TABLE 55. SUN PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT

TABLE 56. SUN PHARMACEUTICAL INDUSTRIES LIMITED: OPERATING BUSINESS SEGMENTS

TABLE 57. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO

TABLE 58. SUN PHARMACEUTICAL INDUSTRIES LIMITED: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 59. SUN PHARMACEUTICAL INDUSTRIES LIMITED: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 60. SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGY

TABLE 61. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT

TABLE 62. TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING BUSINESS SEGMENTS

TABLE 63. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO

TABLE 64. TEVA PHARMACEUTICAL INDUSTRIES LTD.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 65. TEVA PHARMACEUTICAL INDUSTRIES LTD.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 66. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGY

TABLE 67. JOHNSON AND JOHNSON: COMPANY SNAPSHOT

TABLE 68. JOHNSON AND JOHNSON: OPERATING BUSINESS SEGMENTS

TABLE 69. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO

TABLE 70. JOHNSON AND JOHNSON: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 71. JOHNSON AND JOHNSON: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 72. JOHNSON AND JOHNSON: KEY STRATERGY

TABLE 73. STRATA SKIN SCIENCES, INC.: COMPANY SNAPSHOT

TABLE 74. STRATA SKIN SCIENCES, INC.: OPERATING BUSINESS SEGMENTS

TABLE 75. STRATA SKIN SCIENCES, INC.: PRODUCT PORTFOLIO

TABLE 76. STRATA SKIN SCIENCES, INC.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 77. STRATA SKIN SCIENCES, INC.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 78. STRATA SKIN SCIENCES, INC.: KEY STRATERGY

TABLE 79. MAYNE PHARMA GROUP LIMITED: COMPANY SNAPSHOT

TABLE 80. MAYNE PHARMA GROUP LIMITED: OPERATING BUSINESS SEGMENTS

TABLE 81. MAYNE PHARMA GROUP LIMITED: PRODUCT PORTFOLIO

TABLE 82. MAYNE PHARMA GROUP LIMITED: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 83. MAYNE PHARMA GROUP LIMITED: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 84. MAYNE PHARMA GROUP LIMITED: KEY STRATERGY

TABLE 85. PFIZER, INC.: COMPANY SNAPSHOT

TABLE 86. PFIZER, INC.: OPERATING BUSINESS SEGMENTS

TABLE 87. PFIZER, INC.: PRODUCT PORTFOLIO

TABLE 88. PFIZER, INC.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 89. PFIZER, INC.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 90. PFIZER, INC.: KEY STRATERGY

LIST OF FIGURES

FIGURE 1. BARGAINING POWER OF SUPPLIERS

FIGURE 2. BARGAINING POWER OF BUYERS

FIGURE 3. DEGREE OF COMPETITION

FIGURE 4. THREAT OF SUBSTITUTE

FIGURE 5. THREAT OF NEW ENTRANTS

FIGURE 6. NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE, 2023-2030, (MILLION USD)

FIGURE 7. INFLAMMATORY ACNE , MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 8. NON-INFLAMMATORY ACNE, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 9. NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION, 2023-2030, (MILLION USD)

FIGURE 10. TOPICAL MEDICATIONS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 11. ORAL MEDICATIONS , MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 12. NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS, 2023-2030, (MILLION USD)

FIGURE 13. RETINOIDS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 14. ANTIBIOTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 15. SALICYLIC ACID, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 16. BENZOYL PEROXIDE, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 17. OTHERS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 18. NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL, 2023-2030, (MILLION USD)

FIGURE 19. MED SPA, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 20. AESTHETICIAN, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 21. DERMATOLOGIST, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 22. OTHER PROFESSIONAL CHANNELS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 23. NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY REGION 2023-2030, (MILLION USD)

FIGURE 24. UNITED STATES NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE 2023-2030, (MILLION USD)

FIGURE 25. UNITED STATES NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION 2023-2030, (MILLION USD)

FIGURE 26. UNITED STATES NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS 2023-2030, (MILLION USD)

FIGURE 27. UNITED STATES NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL 2023-2030, (MILLION USD)

FIGURE 28. CANADA NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE 2023-2030, (MILLION USD)

FIGURE 29. CANADA NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION 2023-2030, (MILLION USD)

FIGURE 30. CANADA NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS 2023-2030, (MILLION USD)

FIGURE 31. CANADA NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL 2023-2030, (MILLION USD)

FIGURE 32. MEXICO NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE 2023-2030, (MILLION USD)

FIGURE 33. MEXICO NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION 2023-2030, (MILLION USD)

FIGURE 34. MEXICO NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS 2023-2030, (MILLION USD)

FIGURE 35. MEXICO NORTH AMERICA PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL 2023-2030, (MILLION USD)

FIGURE 36. ALMIRALL S.A.: NET SALES, (2021-2023)

FIGURE 37. ALMIRALL S.A.: PRIMARY MARKET COMPETITORS

FIGURE 38. BAUSCH HEALTH COMPANIES, INC.: NET SALES, (2021-2023)

FIGURE 39. BAUSCH HEALTH COMPANIES, INC.: PRIMARY MARKET COMPETITORS

FIGURE 40. GLAXOSMITHKLINE PLC (GSK): NET SALES, (2021-2023)

FIGURE 41. GLAXOSMITHKLINE PLC (GSK): PRIMARY MARKET COMPETITORS

FIGURE 42. GALDERMA S.A.: NET SALES, (2021-2023)

FIGURE 43. GALDERMA S.A.: PRIMARY MARKET COMPETITORS

FIGURE 44. SUN PHARMACEUTICAL INDUSTRIES LIMITED: NET SALES, (2021-2023)

FIGURE 45. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRIMARY MARKET COMPETITORS

FIGURE 46. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, (2021-2023)

FIGURE 47. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRIMARY MARKET COMPETITORS

FIGURE 48. JOHNSON AND JOHNSON: NET SALES, (2021-2023)

FIGURE 49. JOHNSON AND JOHNSON: PRIMARY MARKET COMPETITORS

FIGURE 50. STRATA SKIN SCIENCES, INC.: NET SALES, (2021-2023)

FIGURE 51. STRATA SKIN SCIENCES, INC.: PRIMARY MARKET COMPETITORS

FIGURE 52. MAYNE PHARMA GROUP LIMITED: NET SALES, (2021-2023)

FIGURE 53. MAYNE PHARMA GROUP LIMITED: PRIMARY MARKET COMPETITORS

FIGURE 54. PFIZER, INC.: NET SALES, (2021-2023)

FIGURE 55. PFIZER, INC.: PRIMARY MARKET COMPETITORS

KEY PLAYERS

  • Almirall SA

  • Bausch Health Companies, Inc.

  • GlaxoSmithKline Plc (GSK)

  • Galderma SA

  • Sun Pharmaceutical Industries Limited

  • Teva Pharmaceutical Industries Ltd.

  • Johnson & Johnson

  • STRATA Skin Sciences, Inc.

  • Mayne Pharma Group Limited

  • Pfizer, Inc.


Frequently Asked Questions
What will be the worth of the North America Professional acne medication market by the end of 2030?

According to the report published by the Next Move Consulting, the North American professional acne medication market business is expected to hit at USD 2122.38 million by 2030.

What are the leading companies in the North American professional acne medication market?

The North American professional acne medication industry includes several market players such as Almirall SA, Bausch Health Companies, Inc., GlaxoSmithKline Plc (GSK), Galderma SA, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Johnson & Johnson, STRATA Skin Sciences, Inc., Mayne Pharma Group Limited, and Pfizer, Inc., and others.

What are the market segmentations and scope of the study for the North American professional acne medication industry?

The North American professional acne medication market share is segmented based on acne type, formulation, therapeutic class, distribution channel, and geography.

What are the factors that are driving the growth of the professional acne medication market in North America?

The growth of the professional acne medication market in North America is primarily driven by the rapid expansion of dermatology clinics, along with increased demand for acne treatment due to technological advancements.

What is restraining the growth of the North American professional acne medication market?

The high treatment costs of professional acne medication present a substantial restraint on the market's growth in North America.